Drugs / PF-04523655
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00725686 | Feb 2007 → Nov 2010 | age-related macular degeneration | Quark Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01445899 | Feb 2012 → Nov 2013 | choroidal neovascularization, diabetic macular edema | Quark Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00713518 | Nov 2009 → Nov 2010 | age-related macular degeneration | Quark Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00701181 | Jun 2008 → Jan 2011 | diabetic macular edema | Quark Pharmaceuticals | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-03-21 | Silence Therapeutics GmbH | Results Quark Pharmaceuticals Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema silence-therapeutics.com ↗
In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-03-21 | Silence Therapeutics GmbH | Quark Pharmaceuticals Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema silence-therapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04523655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00713518 ↗ |
| Modality | Small interfering RNA (siRNA) | “a 19-nucleotide methylated double stranded siRNA targeting the RTP801 gene” PMID 23074206 ↗ Nov 2012 |
| Route | Intravitreal | “PF-04523655 intravitreal injections” PMID 23074206 ↗ Nov 2012 |
| Target | RTP801 | “a 19-nucleotide methylated double stranded siRNA targeting the RTP801 gene” PMID 23074206 ↗ Nov 2012 |